### AMENDED FORM 11

### NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: Vodis Pharmaceuticals Inc. (the "Issuer").

Trading Symbol: VP

Date: May 4, 2017

### **1.** New Options Granted:

Date of Grant: April 4, 2017

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Soy Garipoglu	Consultant	No	100,000	\$0.42	April 4, 2022	Nil
Ron Friesen	Consultant	No	10,000	\$0.42	April 4, 2022	Nil
Stanimir Georgiev	Consultant	No	40,000	\$0.42	April 4, 2022	Nil
Noah Dotson	Consultant	No	30,000	\$0.42	April 4, 2022	Nil

Total Number of optioned shares proposed for acceptance: **<u>180,000</u>** 

### FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

### 2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares <sup>(1)</sup>	Exercise Price	Original Date of Grant	Expiry Date
Bill Good	62,500	\$0.60	October 22, 2015	October 22, 2017
Stanimir Georgiev	62,500	\$0.80	November 26, 2015	November 26, 2020
Plamen Ovagemov	75,000	\$0.80	November 26, 2015	November 26, 2020
Kliment Stefanov	75,000	\$0.80	November 26, 2015	November 26, 2020
Otto Folprecht	62,500	\$0.76	January 6, 2016	January 6, 2021
Ivan Miliovski	62,500	\$0.76	January 6, 2016	January 6, 2021
Monica Martinez	7,813	\$0.40	April 4, 2016	April 4, 2018
James Bateman	31,250	\$0.40	April 4, 2016	April 4, 2018
Derek Good	125,000	\$0.18	September 14, 2016	September 14, 2021
Ivan Miliovski	125,000	\$0.18	September 14, 2016	September 14, 2021
Plamen Ovagemov	125,000	\$0.18	September 14, 2016	September 14, 2021

(1) Set out number of optioned shares for each grant with different terms.

### 3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

### Shareholder approval was not required for the grant of options.

(b) State the date of the news release announcing the grant of options.

### Not applicable.

(c) State the total issued and outstanding share capital at the date of grant or amendment.

## As of the date of grant, a total of 28,558,637 common shares of the Issuer are issued and outstanding.

### FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

# The aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options represent 3.48% of the issued and outstanding shares of the Issuer.

(e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

### The number of remaining shares reserved for issuance under the Issuer's Stock Option Plan equals 1,407,500.

(f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

### Not applicable.

(g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

There are no proposed material changes in the affairs of the Issuer.

#### FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

### 4. Certificate of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated May 4, 2017

Ivan Miliovski Name of Director or Senior Officer

<u>/s/ "Ivan Miliovski"</u> Signature

Chief Executive Officer/Director Official Capacity

#### FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT